Anti-TNFRSF10B, AlpHcAbs® Human antibody

Details and Advantages

Code: 300-765-001

Specification:

Applications: ELISA,Flow Cyt

Reactivity: Human

Conjugate: Unconjugated

Advantages:

High lot-to-lot consistency Increased sensitivity and higher affinity Animal-free production

Product Description Manual MSDS FAQ Citations

Product Detail

Description:
Anti-TNFRSF10B, AlpHcAbs® Human antibody is designed for detecting human TNFRSF10B specifically. Based on ELISA and/or FCM, Anti-TNFRSF10B, AlpHcAbs® Human antibody reacts with human TNFRSF10B specifically.

Immunogen: Recombinant human TNFRSF10B
Host: Alpaca pacous
Isotype: Human IgG1
Conjugate: Unconjugated
Specificity: Human TNFRSF10B
Purity: Recombinant Expression and Affinity purified
Concentration: 1mg/ml
Formation: Liquid, 10mM PBS (pH 7.5), 0.05% sucrose, 0.1% trehalose, 0.01% proclin300, 50% Glycerol
Storage: Store at –20 °C, (Avoid freeze / thaw cycles)

Background:
DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.

FAQ

Citations